Action plan for optimizing the design of clinical trials in chronic kidney disease

IF 19.3 2区医学 Q1 UROLOGY & NEPHROLOGY Kidney International Supplements Pub Date : 2017-10-01 DOI:10.1016/j.kisu.2017.07.009

Vlado Perkovic , Jonathan C. Craig , Worawon Chailimpamontree , Caroline S. Fox , Guillermo Garcia-Garcia , Mohammed Benghanem Gharbi , Meg J. Jardine , Ikechi G. Okpechi , Neesh Pannu , Benedicte Stengel , Katherine R. Tuttle , Katrin Uhlig , Andrew S. Levey

{"title":"Action plan for optimizing the design of clinical trials in chronic kidney disease","authors":"Vlado Perkovic , Jonathan C. Craig , Worawon Chailimpamontree , Caroline S. Fox , Guillermo Garcia-Garcia , Mohammed Benghanem Gharbi , Meg J. Jardine , Ikechi G. Okpechi , Neesh Pannu , Benedicte Stengel , Katherine R. Tuttle , Katrin Uhlig , Andrew S. Levey","doi":"10.1016/j.kisu.2017.07.009","DOIUrl":null,"url":null,"abstract":"<div><p>High-quality clinical trials are the cornerstone of evidence-based prevention and treatment of a disease, but nephrology has a strikingly weak base of such trials. Building the evidence base to improve outcomes for people with a kidney disease, therefore, requires both greater quantity and quality of clinical trials. To address these issues, we propose that we aim to enroll 30% of people with chronic kidney disease in trials by 2030. Goal 1: Strongly encourage and promote the conduct of clinical trials in people with chronic kidney disease to increase the number of clinical trials conducted. Goal 2: Optimize the design of clinical trials in people with chronic kidney disease. Goal 3: Increase the capacity for conducting clinical trials in people with chronic kidney disease.</p></div>","PeriodicalId":48895,"journal":{"name":"Kidney International Supplements","volume":"7 2","pages":"Pages 138-144"},"PeriodicalIF":19.3000,"publicationDate":"2017-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.kisu.2017.07.009","citationCount":"18","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Kidney International Supplements","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2157171617300357","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 18

Abstract

High-quality clinical trials are the cornerstone of evidence-based prevention and treatment of a disease, but nephrology has a strikingly weak base of such trials. Building the evidence base to improve outcomes for people with a kidney disease, therefore, requires both greater quantity and quality of clinical trials. To address these issues, we propose that we aim to enroll 30% of people with chronic kidney disease in trials by 2030. Goal 1: Strongly encourage and promote the conduct of clinical trials in people with chronic kidney disease to increase the number of clinical trials conducted. Goal 2: Optimize the design of clinical trials in people with chronic kidney disease. Goal 3: Increase the capacity for conducting clinical trials in people with chronic kidney disease.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

优化慢性肾脏疾病临床试验设计的行动计划

高质量的临床试验是基于证据的疾病预防和治疗的基石，但肾脏病学的此类试验基础非常薄弱。因此，建立改善肾病患者预后的证据基础，需要更多数量和质量的临床试验。为了解决这些问题，我们建议我们的目标是到2030年将30%的慢性肾脏疾病患者纳入试验。目标1:大力鼓励和推动在慢性肾脏疾病患者中开展临床试验，增加临床试验数量。目标2:优化慢性肾病患者的临床试验设计。目标3:提高对慢性肾脏疾病患者进行临床试验的能力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Kidney International Supplements UROLOGY & NEPHROLOGY-

CiteScore

11.80

自引率

0.00%

发文量

期刊介绍： Kidney International Supplements is published on behalf of the International Society of Nephrology (ISN) and comes complimentary as part of a subscription to Kidney International. Kidney International Supplements is a peer-reviewed journal whose focus is sponsored, topical content of interest to the nephrology community.